Adaptive Biotechnologies (ADPT) Receivables - Net (2018 - 2026)

Adaptive Biotechnologies has disclosed Receivables - Net across 9 years of filings, most recently posting $49.5 million for Q2 2026.

• In Q2 2026, Receivables - Net rose 11.81% year-over-year to $49.5 million; the TTM figure through Jun 2026 stood at $49.5 million (up 11.81% YoY), while the FY2025 annual figure was $50.4 million, up 20.69% from the prior year.
• Receivables - Net came in at $49.5 million for Q2 2026 at Adaptive Biotechnologies, up from $48.3 million in the prior quarter.
• In the past five years, Receivables - Net ranged from a high of $50.4 million in Q4 2025 to a low of $22.5 million in Q1 2022.
• Average Receivables - Net over 5 years is $38.1 million, with a median of $40.4 million recorded in 2022.
• Year-over-year, Receivables - Net soared 130.09% in 2022 and declined 5.21% in 2023.
• Over 5 years, Receivables - Net stood at $40.1 million in 2022, then declined by 5.21% to $38.0 million in 2023, then climbed by 9.91% to $41.7 million in 2024, then rose by 20.69% to $50.4 million in 2025, then declined by 1.69% to $49.5 million in 2026.
• Per Business Quant data, the three most recent Receivables - Net figures were $49.5 million in Q2 2026, $48.3 million in Q1 2026, and $50.4 million in Q4 2025.